By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11 rue de MOLSHEIM, 67082
Cedex      France
Phone: 011-33-3-88-27-91-21 Fax: 011-33-3-88-27-91-11



Gene Therapy


Human Genome Sciences, Inc.  Gene Therapy Partnerships

Company News
TRANSGENE (ENX:TNG) Launches Invir.IOTM, Its Integrated Platform For The Next Generation Of Multifunctional Oncolytic Viruses 9/21/2017 11:40:15 AM
TRANSGENE (ENX:TNG): First Patient Treated In A Phase Ib/II Trial Of TG4001 In Combination With Avelumab In HPV-Positive Cancers 9/19/2017 11:00:03 AM
TRANSGENE (ENX:TNG): First Half-Year 2017 In Line With Our Objectives: All Clinical Programs Progressing And New Collaboration Agreements Signed 9/13/2017 11:59:39 AM
TRANSGENE (ENX:TNG) Receives FDA IND Approval To Begin A Clinical Trial With TG4010 + Nivolumab + Chemotherapy In The First-Line Treatment Of Lung Cancer (NSCLC) 9/11/2017 11:52:50 AM
TRANSGENE (ENX:TNG) And Institut BergoniĆ© Present A Poster On The Metromajx Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) At ESMO 2017 Congress 9/8/2017 7:22:28 AM
TRANSGENE (ENX:TNG) Announces Upcoming Investor Meetings 8/31/2017 2:38:09 PM
TRANSGENE (ENX:TNG) Release: First Patient Dosed In A Phase 1/2 Trial Of Pexa-Vec + Opdivo For The First-Line Treatment Of Advanced Liver Cancer 7/31/2017 12:25:37 PM
TRANSGENE (ENX:TNG) Announces Cancer Research Publication Confirming The Potential Of Its Next Generation Armed Engineered Oncolytic Virus 7/24/2017 12:26:44 PM
Servier And TRANSGENE (ENX:TNG) Have Become Partners To Apply Viral Vectorization Technology To The Engineering Of Allogenic CAR-T 6/29/2017 6:30:52 AM
TRANSGENE (ENX:TNG) Hosts Immuno-Oncology R&D Day Focused On Modulating The Tumor Micro-Environment In Paris 6/22/2017 6:49:19 AM